Gossamer Bio

Gossamer Bio, Inc., is a clinical-stage biopharmaceutical public company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Nasdaq ticker is GOSS.

Gossamer Bio was founded in 2015 and is based in San Diego, California, USA. The company has office also in Dublin, Ireland.

The Company has six programs: three clinical-stage product candidates and three preclinical programs. Its pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology program. GB001 is an oral antagonist of prostaglandin D2 receptor 2, or DP2, is being developed for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. GB1275 is a CD11b agonist. GB5121 and GB7208 are both central nervous system-penetrant Bruton’s tyrosine kinase (BTK) inhibitors, a drug class that has been rapidly replacing chemotherapy in a number of blood cancers.

“These two promising product candidates are the result of intensive internal research, and we are excited to advance them into the clinic where there remains a high unmet need in treating malignant brain tumors and neurologic diseases,” said Faheem Hasnain, Chairman, co-founder and CEO of Gossamer Bio.

Сlinical trials:

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH). GB002 is an orally inhaled, small molecule, selective platelet-derived growth factor, or PDGF, receptor kinase inhibitor is being developed for the treatment of pulmonary arterial hypertension.

GB004 in Adult Subjects With Active Ulcerative Colitis (UC). GB004 is being developed for Inflammatory Bowel Disease (IBD).

GB5121 in Primary CNS Lymphoma, Oral CNS-Penetrant BTK Inhibitor.

GB5121: Oral, CNS-Penetrant, Irreversible BTK Inhibitor for Treatment of PCNSL

Superior CNS penetration in preclinical models compared to other BTK inhibitors in development for oncology

Highly selective for BTK, with no non-TEC kinases inhibited at greater than 50% in a broad kinome scan

First-in-human Phase 1 clinical trial expected to initiate in the fourth quarter of 2021

First-in-patient Phase 1b/2 clinical trial in patients with relapsed / refractory CNS lymphoma expected to initiate in the first half of 2022

Relapsed and refractory PCNSL provides potential accelerated path to registration

GB7208: Oral, CNS-Penetrant, Irreversible BTK Inhibitor for Treatment of MS

Potentially best-in-class brain penetrance among BTK inhibitors being developed for neuroinflammatory and neurodegenerative diseases based on pre-clinical models

In a BTK-dependent pre-clinical disease model, demonstrated superiority vs. tolebrutinib, a CNS-penetrant BTK inhibitor in Phase 3 development for MS

Potent inhibition of microglia inflammation in vitro and in vivo

First-in-human Phase 1 clinical trial expected to initiate in the second half of 2022